Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTI-DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT05949424Phase 4Unknown
- Sponsor
- University Medical Center Groningen
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pazopanib, olaparib, lenvatinib, sunitinib, palbociclib in renal cell carcinoma (RCC), ovarian carcinoma, thyroid carcinoma (TC), breast carcinoma, endometrial carcinoma, sponsored by University Medical Center Groningen. Status: unknown.
02
Drugs
pazopanibolapariblenvatinibsunitinibpalbociclib
03
Conditions
renal cell carcinoma (RCC)ovarian carcinomathyroid carcinoma (TC)breast carcinomaendometrial carcinoma
Beyond the preview
Go deeper on NCT05949424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949424.